Catalyst Dossier · compiled by CeliA 🧫
Imunon, Inc. (IMNN)
Pharmaceutical Preparations · market cap $8M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
5
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Imunon, Inc. (IMNN) is a micro-cap clinical-stage pharmaceutical company with a market cap of approximately $7M and roughly 4.2 million shares outstanding at ~$1.77. Its lead asset, IMNN-001, is an IL-12 plasmid formulated with a PEG-PEI-Cholesterol lipopolymer in Phase 3 for epithelial ovarian cancer, with a broader pipeline including ThermoDox in hepatocellular carcinoma and breast cancer, and a paclitaxel Phase 2 in ovarian cancer. The company faces acute financial distress with only $4.8M cash and an estimated 3.6-month runway.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| IMNN-101 | Phase 2 | SARS CoV 2 Infection |
| IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) | Phase 3 | Epithelial Ovarian Cancer |
| ThermoDox | Phase 3 | Hepatocellular Carcinoma |
| ThermoDox in combination with Microwave Hyperthermia (heat) | Phase 2 | Breast Cancer |
| IMNN-001 | Phase 2 | Epithelial Ovarian Cancer |
Price & technical context
3-month
-43.6%
6-month
-52.4%
12-month
-78.1%
52-wk range
$1.51–$8.00
vs 50-day MA
-16.7%
vs 200-day MA
-48.7%
Realized vol
52.6%
Max drawdown
-96.5%
Daily closes through 2026-08-03. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IMNN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.